We want to challenge and improve today's standardized treatments with the help of our AI-Immunology™ platform. In the field of oncology, we create truly personalized therapies where one size fits one, and only one. Within infectious diseases, we use the technology to design next-generation vaccines to address unmet medical needs.
Evaxion's pioneering AI-Immunology™ platform accelerates fast and effective vaccine target discovery, drug design, and development. Using the power of AI, our platform simulates the human immune system and generates predictive models to identify and develop personalized and other next-generation immunotherapies for patients.
A broad pipeline of unique, world-class candidates with the potential to revolutionize the prevention and treatment of cancer and infectious disease. Our AI-Immunology™ platform enables a high level of scalability, offering the potential to expand our portfolio and our proprietary platforms to the benefit of patients worldwide.
At the forefront of biotechnological innovation, our cutting-edge research is dedicated to advancing vaccine immunotherapies to battle cancer and infectious diseases. With a wide range of multidisciplinary capabilities, our research allows for continuous iterative learning loops which accelerates the development of transformative treatments and significantly enhance the value of our platform.
Since 2021, Evaxion has been listed on the Nasdaq Capital Market exchange (ticker code: EVAX). Here you can find all of the latest Evaxion investor insights: our results, upcoming events and news, important shareholder updates and much more.
We believe collaborating with leading and like-minded partners will create the best-in-class vaccines for patients. Our business model is geared toward a multi-partner approach focused around single or multiple vaccine target discovery, drug design and development agreements
Stay informed with Evaxion’s latest press releases, events, scientific posters and publications, and media resources.
Evaxion > News & resources
Evaxion to present new data for EVX-04, an off-the-shelf therapeutic vaccine for acute myeloid leukemia, at the EHA 2026 Congress
Evaxion announces business update and first quarter 2026 financial results
Evaxion to announce business update and first quarter 2026 financial results on May 7, 2026
MAY 13, 2026
Scientific posters
CIMT 2026
Immune signatures associated with clinical response to the personalized neoantigen vaccine EVX-01 and pembrolizumab in advanced melanoma
MAY 4, 2026
Vaccinology: A New Era in Immune-Driven Vaccine Design
AI-Immunology™: An Artificial Intelligence Platform Advancing Vaccine Development Across AMR Bacteria and Viral Pathogens
APR 22, 2026
AACR 2026
Endogenous Retrovirus–Derived Neoantigens Enable a Personalized Cancer Vaccine Strategy for Glioblastoma
AI-designed personalized neoantigen vaccine, EVX-01, induces durable de novo T-cell responses in advanced melanoma patients
DEC 6, 2025
Scientific presentations
67th ASH Annual Meeting
Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting. With hundreds of sessions, thousands of abstracts, and countless ways to experience the best in hematology, the ASH annual meeting is the world’s premier global hematology event.
NOV 7, 2025
SITC 2025
Immune correlates of clinical response following treatment with the personalized cancer vaccine EVX-01 and pembrolizumab in advanced melanoma patients.
